

# Serratiopeptidase: The Healing Enzyme

Miss. Payal S. Rakshe<sup>1</sup>, Miss. Jagruti V. Kumbhar<sup>2</sup>, Mr. Abhijit V. Tambe<sup>3</sup>

Students, B Pharmacy<sup>1,2,3</sup>

Samarth Institute of Pharmacy, Pune, Maharashtra, India

**Abstract:** *Inflammation is still a major factor in the majority of diseases and physiological imbalances. Acute inflammation is a protective mechanism used by the immune system to remove the source of inflammation, and failure to resolve it leads to chronic inflammation. In other words, inflammation is a cleansing process that helps to maintain homeostasis by removing invading materials and noxious alterations. Serratiopeptidase, a proteolytic enzyme from the trypsin family, has a wide range of applications in the fight against inflammation. Nonsteroidal anti-inflammatory medicines (NSAIDs) are the most commonly used treatments to treat acute inflammation, either alone or in combination with other medications. These medications have a number of drawbacks, including side effects, adverse drug reactions, and so on. Enzyme-based anti-inflammatory medications have become more popular than chemical-based anti-inflammatory drugs as a result of these limitations and consequences.*

**Keywords:** Serratiopeptidase, Inflammation, Proteolytic enzyme, Enzyme therapeutics.

## REFERENCE

- [1]. K.D. Rainsford, Anti-inflammatory drugs in the 21st century, Subcell Biochem, 42 (2007), pp. 3-27
- [2]. A. Bertolini, A. Ottani, M. Sandrini, Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks, Curr Med Chem, 9 (10) (2002), pp. 1033-1043
- [3]. S. Steiger, J.L. Harper, Mechanisms of spontaneous resolution of acute gouty inflammation, Curr Rheumatol Rep, 16 (1) (2014), p. 392
- [4]. K.K. Joshi, R.P. Nerurkar, Anti-inflammatory effect of the serratiopeptidase—rationale or fashionable: a study in rat paw edema model induced by the carrageenan, Indian J Physiol Pharmacol, 56 (4) (2012), pp. 367-374
- [5]. P.C. Malshe, orally administered serratiopeptidase: can it work? J Assoc Physicians India, 46 (5) (1998), p. 492
- [6]. Rakoff-Nahoum S., Why cancer and inflammation? Yale J Biol Med 2006;79(3-4):123-130.
- [7]. Coussens LM, Werb Z., Inflammation and cancer. Nature 2002;420(6917):860-867. doi:10.1038/nature01322
- [8]. Dobrovol'skaia MA, Kozlov SV., Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curr Cancer Drug Targets 2005;5(5):325-344
- [9]. Cooney DA, Rosenbluth RJ., Enzymes as therapeutic agents. Adv Pharmacol Chemother 1975;12:185-289
- [10]. [10] Amadasi A, Bertoldi M, Contestabile R, et al., Pyridoxal 5'-phosphate enzymes as targets for therapeutic agents., Curr Med Chem 2007;14(12):1291-1324.
- [11]. Rossi JJ, Sarver N., RNA enzymes (ribozymes) as antiviral therapeutic agents. Trends Biotechnol 1990;8(7):179-183
- [12]. Tasaka K, Meshi T, Akagi M, et al., Anti-inflammatory activity of a proteolytic enzyme, Prozime-10. Pharmacology 1980;21(1):43-52.
- [13]. Verma MK, Sobha K., In-vitro evaluation of antioxidant and anti-inflammatory properties of autolysed extract of the Indian earthworm Pheretima Posthuma. Res J Pharm Biol Chem Sci 2013;4(4):888-898.
- [14]. Verma MK, Pulicherla KK., Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements. AAPS PharmSciTech 2015;16(2):223-233.
- [15]. Verma MK, Sobha K., Understanding mechanism genetic risk factors in the beginning and progression of rheumatoid arthritis – current scenario and future prospect. Inflamm Res 2015;64(9):647-659
- [16]. Klein G, Kullich W., Short-term treatment of painful osteoarthritis of the knee with oral enzymes. A randomized, double-blind study versus diclofenac. Clin Drug Invest 2000;19:15-23.

- [17]. Yamasaki H, Tsuji H, Saeki K., Anti-inflammatory action of a protease, TSP, produced by *Serratia*. *Folia Pharmacol Japan*. 1967; 63:302-14.
- [18]. Aiyappa PS, Harris JO., The extracellular metalloprotease of *Serratia marcescens*. I. Purification and characterization. *Mol Cell Biochem*. 1976; 13:95-100.
- [19]. Tanimoto T, Fukuda H, Kawamura J., On the quality of enzyme preparation (V): *Serratiopeptidase* preparation. *Eisei Shikenjo Hokoku*. 1983; 101:92-5.
- [20]. Kim N, Kim SI., Metal ion relevance for the stability and activity of a 52-kDa *Serratia* proteinase. *Biotechnol Biochem*. 1993; 57:29-33.
- [21]. Borges EL, Mares-Guia M., Are proteases used as anti-inflammatory agents in reality accelerating the inflammatory process. *Med Hypotheses*. 2000; 54:453-5.
- [22]. Sherry S, Fletcher AP., Proteolytic enzymes: a therapeutic evaluation. *Clin Pharmacol Ther*. 1960; 1:202-26.
- [23]. Esch PM, Gerngross H, Fabian A., Reduction of postoperative swelling Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase- A prospective study. *Fortschr Med*. 1989; 107:67-8
- [24]. Miyata K., Intestinal absorption of *Serratia* Peptidase. *J Appl Biochem*. 1980; 2:111-6.
- [25]. Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma A., Intestinal absorption of serrapeptase (TSP) in rats. *Biotechnol Appl Biochem*. 1994; 20:101-8.
- [26]. Kee WH, Tan SL, Lee V, Salmon YM., The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. *Singapore Med J*. 1989; 30:48-54
- [27]. Shimura S, Okubo T, Maeda S, Aoki T, Tomioka M, Shindo Y, Takishima T, Umeya K., Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo. *Biorheology*. 1983; 20:677-83.
- [28]. Aratani H, Tateishi H, Negita S., Studies on the distributions of antibiotics in the oral tissues: Experimental staphylococcal infection in rats, and effect of *serratiopeptidase* on the distributions of antibiotics. *J Antibiot*. 1980; 33:623-35.
- [29]. Panagariya A, Sharma AK., A preliminary trial of *serratiopeptidase* in patients with carpal tunnel syndrome. *J Assoc Physicians India*. 1999; 47:1170-72.
- [30]. Bracale G, Selvetella L., Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus *serratio-peptidase*. *Minerva Cardioangiol*. 1996; 44:515-24.
- [31]. Maheshwari M, Miglani G, Mali A, Paradkar A, Yamamura S, Kadam S., Development of Tetracycline-*Serratiopeptidase* Containing Periodontal Gel: Formulation and Preliminary Clinical Study. *AAPS PharmSciTech*. 2006; 7: Article 76.
- [32]. Okumura H, Watanabe R, Kotoura Y, Nakane Y, Tangiku O., Effects of a proteolytic-enzyme preparation used concomitantly with an antibiotic in osteoarticular infections (author's transl). *Jpn J Antibiot*. 1977; 30:223-7.
- [33]. Khateeb TA, Nusair Y., Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. *Int J Oral Maxillofac Surg* 2008;37:264e8
- [34]. <http://www.quantumjunction.com/Research.htm>
- [35]. Majima Y, Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura Y., The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. *Arch Otorhinolaryngol*. 1988; 244:355-9.
- [36]. Majima Y, Hirata K, Takeuchi K, Hattori M, Sakakura Y., Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. *Am Rev Respir Dis*. 1990; 141:79-83.
- [37]. Suzuki K, Niho T, Yamada H, Yamaguchi K, Ohnishi H., Experimental study of the effects of bromelain on the sputum consistency in rabbits. *Nippon Yakurigaku Zasshi*. 1983; 81:211-6.
- [38]. Tago T, Mitsui S., Effects of Serrapeptase in dissolution of sputum, especially in patients with bronchial asthma. *Jap Clin Exp Med*. 1972; 49:222-228.
- [39]. Artini M, Passariello C, Russo P, Schippa S, Poggiali F, Costerton W, Selan L., Modulation of *AtIE* gene product by *serratiopeptidase* reverts *Staphylococcus epidermidis* biofilm to antibiotic sensibility of the planktonic form. *ASM Conferences Cell-Cell Communication in Bacteria*. Banff, Alberta. 23-27 July 2004.
- [40]. Russo P, Ripavecchia V, Poggiali F, Passariello C, Schippa S, Artini M, Selan L., Reduction of in vitro resistance of bacterial biofilms to antibiotics by inhibition of biofilm formation process. 44th annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA. 30 Oct, 2 Nov 2004.

- [41]. Malshe PC., A preliminary trial of serratiopeptidase in patients with carpal tunnel Syndrome. J Assoc Physicians India. 2000; 48:1130-32. AAPS PharmSciTech. 2006; 7: Article 76.
- [42]. Nieper HA, Silk Worm Enzymes for Carotid Artery Blockage. <http://www.serrapeptase.info/Dr-H-A-Nieper.htm>.
- [43]. Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR, Thaller MC., Proteolytic enzymes: a new treatment strategy for prosthetic infections. Ant Aging Chemoth. 1993; 37:2618-21
- [44]. Nihon KS., A case of pneumonitis due to serrapeptase. Gakkai Zasshi 1989; 27:1231-6.
- [45]. Sasaki S, Kawanami R, Motizuki Y, Nakahara Y, Kawamura T, Tanaka A, Watanabe S., Serrapeptase-induced lung injury, 131 manifesting as acute eosinophilic pneumonia. Nihon Kokyuki Gakkai Zasshi. 2000; 38:540-44.